MYC facilitates the sLe (x/a) glycan in CRC cells to initiate the EMT process.33 SUZ12 is positively related to EMT characteristics in oxaliplatin‐resistant DLD1 cells.34 KRAS suppresses the miR‐200 family, which is the vital negative regulator of EMT in multiple human CRC subtypes.35 Furthermore, specific siRNAs of MYC, SUZ12, and KRAS can restore the miR‐487b inhibitor‐induced EMT phenotypes, further demonstrating that MYC, SUZ12, and KRAS are EMT regulatory mediators belonging to miR‐487b in CRC cells. Here, KRAS is linked to colorectal carcinoma.